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16 Inﬂuence of newborn screening on the age of diagnosis in cystic
ﬁbrosis patients
K. Zybert1, M. Mielus1, E. Mierzejewska2, M. Ołtarzewski3, D. Sands1. 1Institute
of Mother and Child, Cystic Fibrosis Center, Warsaw, Poland; 2Institute of Mother
and Child, Department of Epidemiology, Warsaw, Poland; 3Institute of Mother
and Child, Screening Department, Warsaw, Poland
Background: Cystic Fibrosis Newborn screening (CFNBS) as a pilot study started
at the Institute of Mother and Child (IMC) Centre in 1999 and 444 063 newborns
were examined until 2003. Current CFNBS has started gradually in Poland in 2006,
covering the whole country in 2009 and is ongoing. 582 693 children were screened
until the end of 2011. During CFNBS different protocol’s strategies were used.
Aim: Impact of the implementation of NBS on the age of CF diagnosis.
Methods: The study involved children diagnosed and treated only in IMC CF Centre
(from 1999 until the end of 2011). Three groups were formed:
1. Pilot group (p-NBS) − 56 children, according to protocol strategy IRT/IRT and
IRT/IRT/DNA, only F508del mutation was assessed;
2. Current group (c-NBS) − 92 children, IRT/IRT/DNA and IRT/DNA protocol,
with expanded DNA analysis panel;
3. Patient diagnosed clinically (non-NBS) − 56 children.
Moreover, DNA analysis in c-NBS group contains also frequent mutation in Polish
population: 3849+10kbC>T, which is combined with low sweat test values. All
patients underwent sweat tests.
Results: The age of diagnosis was signiﬁcantly lower (both p< 0.001) in p-NBS
(mean 1.4 months) and c-NBS (mean 0.8 month) than in non-NBS group (mean
20.1 months). Median for the 3 groups was 1 month, 1 month and 7 months
respectively. During the ﬁrst month of life 7.1% of children were diagnosed in
p-NBS, 32.6% in c-NBS, 3.6% in non-NBS group. C-NBS was characterized
by higher incidence (6.5%) of 3849+10kcC>T than p-NBS and non-NBS group
(both 0.9%).
Conclusion: IRT/DNA strategy with extended DNA analysis provides an opportu-
nity of earlier CF diagnosis even in children with normal sweat test values.
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Objectives: The Czech nation-wide CF NBS scheme, based on IRT/DNA/IRT
protocol, has been operational since X/2009. We evaluated its screening outcomes
in Bohemia (western region of the Czech Republic accounting for 2/3 of the entire
population) until XII/2013.
Methods: Annual summaries from CF NBS and internal diagnostic database were
used.
Results: From the total of 313,666 screened newborns 3,406 (1.09%) underwent
DNA testing (DT). 337 children were identiﬁed with positive NBS (1 or 2 detected
mutations, IRT recall) of which 48 children with positive sweat test (ST) had
CF (38 with 2 CF-causing mutations in trans, 10 with 1 mutation). None of
the children where no mutation was identiﬁed and whose IRT recall value was
above the recall cut-off level (i.e. fail safe strategy) had positive ST. Extended
DT revealed an additional mutation (Q1476X) in an infant with 1 CF mutation and
repeatedly borderline ST. 199 children with positive NBS had negative ST, including
9 children with equivocal diagnosis of CF (most of whom had R117H;IVS8T/7/
complex allele). ST was not performed in 8 screening positive children due to
parental non-compliance or in deceased infants. In 5 instances CF NBS failed to
identify CF: 3 cases had meconium ileus with IRT below the cut-off and 2 instances
had rare mutations not present in the screening panel accounting for over 90% of
all population speciﬁc alleles.
Conclusion: Current CF NBS protocol is an effective tool for early diagnosis of CF.
However, we plan to adopt IRT/PAP/DNA protocol in a future to improve sensitivity
and to reduce costs of CF NBS by limiting DT.
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Objectives: Newborn screening for cystic ﬁbrosis is done in eastern Saxony since
18 years now. We detected 53 babies with cystic ﬁbrosis through that time. 50
of them we saw in our cystic ﬁbrosis center for sweat testing and conﬁrming the
diagnosis. We looked for clinical signs and symptoms of cystic ﬁbrosis and need
for special therapy at this early stage of life.
Methods: Babies screened positive for cystic ﬁbrosis are seen between 2 and
8 weeks of life for sweat testing in our center. We ask for medical history, do a
weight and height measurement, look for fecal elastase and do a clinical assessment
at this ﬁrst visit.
Results: 18% of the children diagnosed with cystic ﬁbrosis had a meconium
ileus in their history, 84% had pancreatic insufﬁciency diagnosed by absence of
fecal elastase in their stool. More than the half of children showed gastrointestinal
symptoms as stool abnormalities, meteorism, abdominal pain and failure to thrive.
But also pulmonary symptoms like cough, crackles in auscultation and wheezing
where seen in nearly half of the children.
Conclusion: Most of the babies detected by newborn screening show clinical signs
of cystic ﬁbrosis even in their ﬁrst weeks of life and need special therapy. Without
newborn screening in many of them those signs would not have been correlated to
cystic ﬁbrosis and specially treated without newborn screening.
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Newborn screening for CF in Poland was started in 2006. According to our previous
experience, the commercial assays are not appropriate for the Polish population due
to high heterogenity of the CFTR mutations in our CF patients. That is the reason of
IRT/DNA-sequencing strategy implementation. In the ﬁrst step of analysis the most
frequent mutations in seven exons were analyzed according to the recommendation
of the Polish Society of Cystic Fibrosis. Since 2010 protocol was developed by
introduction of second step in which automatically analysis of the remained CFTR
exons is provided for newborns with one identiﬁed mutation. The aim of this study
was evaluation of the effectiveness of the expanded CFTR analysis in screening
programme. Deﬁnition “rare mutation” was determined for a variant which is not
included in the common commercial assays. The group of 9443 newborns was
directed for genetic analysis. In ﬁrst basic step of genetic analysis two pathogenic
mutations were found in 223 cases, in 25 (11.2%) rare or novel mutations were
discovered. A group of 301 newborns with one identiﬁed mutation were directed
for expanded CFTR analysis. In 59 cases second mutation was identiﬁed, and in 42
cases (71.2%) there were rare or novel ones. The 2184insA, 3600+2insT, L997F,
2789+2insA, R1102X and K710X (included in one commercial assay) mutations
should be considered as potential candidates for inclusion to the Polish CFTR panel
as frequent mutations. Summarizing, strategy based on DNA sequencing seems to
be accurate method for screening programme in Poland even at the risk of detection
novel variants without conﬁrmed clinical signiﬁcance.
